Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
January 19, 2009 | Director, President & CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 8,333 | $2.72 | 48,833 | |
January 19, 2009 | Director, President & CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 8,334 | $2.72 | 57,167 | |
January 19, 2009 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 8,334 | $2.72 | 65,344 | |
January 19, 2009 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 8,333 | $2.72 | 73,677 | |
January 19, 2009 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 8,333 | $2.72 | 82,010 | |
November 17, 2008 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 7,000 | $2.76 | 120,462 | |
December 18, 2012 | SVP & Chief Financial Officer | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 8,636 | $2.77 | 37,272 | |
December 18, 2012 | SVP & Chief Financial Officer | Form 4 | Exercise of in-the-money or at-the-money derivative security | 8,636 | $2.77 | -- | |
December 7, 2012 | President & CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 17,271 | $2.77 | 213,285 | |
December 7, 2012 | President & CEO | Form 4 | Exercise of in-the-money or at-the-money derivative security | 17,271 | $2.77 | 17,083 | |
October 15, 2012 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 34,542 | $2.77 | 119,542 | |
October 15, 2012 | Director | Form 4 | Exercise of in-the-money or at-the-money derivative security | 34,542 | $2.77 | 37,083 | |
September 20, 2012 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 34,542 | $2.77 | 347,650 | |
September 20, 2012 | Director | Form 4 | Exercise of in-the-money or at-the-money derivative security | 34,542 | $2.77 | 18,735 | |
May 26, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 34,542 | $2.77 | 34,542 | |
May 26, 2011 | CFO | Form 4 | Open market or private purchase of non-derivative or derivative security | 3,454 | $2.77 | 16,787 | |
May 26, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 25,907 | $2.77 | 33,907 | |
May 26, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 34,542 | $2.77 | 197,104 | |
May 26, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 34,542 | $2.77 | 69,125 | |
May 26, 2011 | CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 17,271 | $2.77 | 161,016 | |
May 26, 2011 | Controller & CAO | Form 4 | Open market or private purchase of non-derivative or derivative security | 1,727 | $2.77 | 12,800 | |
May 26, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 8,636 | $2.77 | 23,636 | |
December 6, 2010 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 30,000 | $2.81 | 30,000 | |
November 14, 2008 | Director, President & CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 3,000 | $2.83 | 32,167 | |
February 19, 2010 | Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 7,537 | $2.94 | 26,537 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.